Deutsche Bank AG Has $4.79 Million Stock Position in Progyny, Inc. (NASDAQ:PGNY)

Deutsche Bank AG lowered its stake in Progyny, Inc. (NASDAQ:PGNY) by 25.5% during the third quarter, Holdings Channel reports. The institutional investor owned 85,625 shares of the company’s stock after selling 29,265 shares during the period. Deutsche Bank AG’s holdings in Progyny were worth $4,794,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Cambridge Investment Research Advisors Inc. boosted its holdings in Progyny by 6.9% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 7,040 shares of the company’s stock valued at $394,000 after purchasing an additional 456 shares during the period. Nordea Investment Management AB lifted its holdings in shares of Progyny by 98.9% during the 3rd quarter. Nordea Investment Management AB now owns 498,734 shares of the company’s stock worth $28,418,000 after acquiring an additional 248,042 shares during the period. Landsberg Bennett & Dubbaneh LLC lifted its holdings in shares of Progyny by 58.3% during the 3rd quarter. Landsberg Bennett & Dubbaneh LLC now owns 5,913 shares of the company’s stock worth $338,000 after acquiring an additional 2,177 shares during the period. Amalgamated Bank lifted its holdings in shares of Progyny by 40.5% during the 3rd quarter. Amalgamated Bank now owns 47,827 shares of the company’s stock worth $2,678,000 after acquiring an additional 13,784 shares during the period. Finally, Texas Permanent School Fund lifted its holdings in shares of Progyny by 83.8% during the 3rd quarter. Texas Permanent School Fund now owns 50,918 shares of the company’s stock worth $2,851,000 after acquiring an additional 23,210 shares during the period. 90.52% of the stock is owned by hedge funds and other institutional investors.

In related news, CEO David J. Schlanger sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 1st. The shares were sold at an average price of $62.24, for a total transaction of $3,112,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Norman Payson sold 8,330 shares of the business’s stock in a transaction that occurred on Wednesday, January 12th. The shares were sold at an average price of $46.52, for a total transaction of $387,511.60. The disclosure for this sale can be found here. Insiders have sold 334,421 shares of company stock valued at $19,286,162 in the last 90 days. 19.40% of the stock is currently owned by corporate insiders.

A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. upped their price objective on shares of Progyny from $65.00 to $79.00 and gave the stock an “overweight” rating in a research report on Friday, October 22nd. Jefferies Financial Group initiated coverage on shares of Progyny in a research report on Wednesday, December 1st. They set a “buy” rating and a $60.00 price objective for the company. Citigroup cut shares of Progyny from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $60.00 to $64.00 in a research report on Monday, November 22nd. Barclays increased their target price on shares of Progyny from $72.00 to $80.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 28th. Finally, Berenberg Bank assumed coverage on shares of Progyny in a research note on Thursday, September 30th. They set a “buy” rating and a $81.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Progyny presently has an average rating of “Buy” and a consensus price target of $68.25.

NASDAQ PGNY opened at $43.19 on Friday. Progyny, Inc. has a 52-week low of $38.61 and a 52-week high of $68.32. The company has a 50-day simple moving average of $51.97 and a 200 day simple moving average of $55.01. The company has a market capitalization of $3.91 billion, a PE ratio of 47.99 and a beta of 1.72.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, November 4th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.11. Progyny had a net margin of 18.96% and a return on equity of 29.67%. The business had revenue of $122.30 million during the quarter, compared to the consensus estimate of $125.52 million. During the same quarter last year, the company posted $0.05 earnings per share. The firm’s quarterly revenue was up 23.7% compared to the same quarter last year. On average, research analysts predict that Progyny, Inc. will post 0.54 earnings per share for the current fiscal year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Read More: Intrinsic Value and Stock Selection

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY).

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.